Dimerix secures US patent protection for DMX-652 through to 2043
Dimerix (ASX: DXB) has been granted a composition of matter patent for DMX-652 by the United States Patent and Trademark Office (USPTO), securing US intellectual property protection for its recently acquired Phase 2-ready acute kidney injury treatment.
The Dimerix DMX-652 US patent protects the compound until at least 11 April 2043, an extension of two years beyond the originally anticipated 2041 date. This uplift was delivered through a USPTO patent term adjustment of 677 days.
DMX-652 is described by the company as a “first and best in class USP30 inhibitor,” designed to prevent kidney injury and promote mitophagy where damage has occurred. The asset was acquired recently, as detailed in the company’s ASX release of 17 July 2026, making this patent grant a follow-on de-risking event for the newly added programme.
When big ASX news breaks, our subscribers know first
Inside the composition of matter patent grant
The clinical-stage biopharmaceutical company confirmed the specifics of the granted patent, which covers the DMX-652 compound and its underlying chemistry.
Key details of the grant include:
-
Patent title: “N-cyanopyrrolidines with activity as USP30 inhibitors”
-
Patent number: US 12,679,833
-
Coverage until 11 April 2043 (including 677 days of patent term adjustment)
-
Granted claims are composition of matter-type claims
-
A divisional application has also been filed to pursue additional claims covering DMX-652
The additional two years of patent life further enhances the commercial attractiveness of the asset.
CEO Commentary
“The granting of this core patent is a key milestone for Dimerix as it strengthens our comprehensive intellectual property portfolio and further protects our new asset, DMX-652, until at least 2043 in the United States,” said Dr Nina Webster, Chief Executive Officer & Managing Director.
Understanding acute kidney injury — the target indication
Acute kidney injury (AKI) is a severe clinical syndrome characterised by a rapid decline in kidney function, often occurring within hours. It arises from several high-risk clinical settings, most notably cardiac surgery and sepsis, and is frequently associated with high morbidity and mortality.
DMX-652 is a selective inhibitor of USP30, a mitochondrial enzyme that slows the removal of damaged mitochondria. By inhibiting USP30, the drug is designed to support mitochondrial quality control in injured kidney cells, promoting mitophagy, which is the process of clearing out damaged mitochondria.
The compound is a small molecule delivered as an oral once-daily capsule. For investors, the central point is the scale of unmet need: there are currently no approved therapies for AKI, representing a clear commercial whitespace.
| Factor | Detail |
|---|---|
| Addressable population | Approx. 260,000/year across US, Germany, France, Italy, Spain and UK — potential orphan designation |
| Incidence after on-pump cardiac surgery | Approx. 1 in 4 patients |
| Approved therapies today | None |
| Delivery | Oral once-daily capsule |
| Initial indication | AKI associated with cardiac surgery |
Why the patent strengthens the Dimerix investment case
The long intellectual property runway to 2043 protects the future revenue potential of the asset should it advance successfully through clinical development. The patent grant is one of several de-risking components that came with the DMX-652 acquisition.
Assets included in the acquisition are:
-
An open IND in the US with a Phase 2 clinical trial protocol that has received approval to proceed by the US Food and Drug Administration (FDA)
-
The composition of matter patent (now granted)
-
Sufficient pharmaceutical grade (GMP) drug product for the Phase 2 trial
-
All manufacturing methodology
According to management, DMX-652 has the potential to positively impact intensive care duration, reduce the need for dialysis, reduce permanent kidney damage and ultimately reduce death rates. These are stated potential benefits rather than proven clinical outcomes.
The programme sits alongside the company’s lead asset DMX-200, currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS). Dimerix reports a network of five commercial partners supporting global development and future market access.
DMX-200 post-trial access is now open to eligible patients who completed the ACTION3 Phase 3 trial, with commercial partners covering supply costs across licensed territories as the programme advances toward its March 2028 primary data readout.
Next steps and what investors should watch
Preparations are underway to initiate the Phase 2 clinical trial in the initial indication of AKI associated with cardiac surgery. Management has stated the asset also has the potential to expand into multiple other indications.
The company has not disclosed a specific trial start date or timeline in the announcement. The strategic logic is clear: the patent grant further de-risks the asset ahead of the planned Phase 2 programme, adding a long protection window to an already Phase 2-ready acquisition.
For investors exploring the broader Dimerix pipeline context, our full explainer on the ACTION3 Phase 3 trial completion covers how 333 patients were enrolled across 21 countries, the significance of exceeding the original 286-patient target, and the path to the March 2028 primary data readout.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news and in-depth analysis directly to your inbox within minutes of release. Join 20,000+ investors already staying ahead of the market on biotech and healthcare announcements. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment market-moving news breaks.